Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "The Tide-A Study - Avelumab + Intermittent Axitinib in Previously Untreated Patients With mRCC"

96 views
November 3, 2023
Comments 0
Login to view comments. Click here to Login